Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Bayer to offload Alzheimer’s imaging agent as part of restructuring?

This article was originally published in Scrip

Executive Summary

Bayer HealthCare is reportedly looking to sell its investigational Alzheimer’s imaging agent florbetaben, as part of efforts to restructure its contrast agent and diagnostics businesses. According to the Financial Times Deutschland, the company plans to create a new subunit combining its contrast agents with its imaging subsidiary Medrad, which develops devices to diagnose and treat cardiovascular diseases. The company would not comment to Scrip about the speculation.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst